Literature DB >> 11801698

Direct comparison of spatially normalized PET and SPECT scans in Alzheimer's disease.

Karl Herholz1, Helge Schopphoff, Mathias Schmidt, Rüdiger Mielke, Wolfgang Eschner, Klemens Scheidhauer, Harald Schicha, Wolf-Dieter Heiss, Klaus Ebmeier.   

Abstract

UNLABELLED: Hexamethylpropyleneamine oxime (HMPAO) SPECT and 18F-FDG PET depict similar aspects of perfusion and metabolic abnormalities in Alzheimer's disease (AD), but the correspondence between them is not known in detail. We therefore used statistical parametric mapping to detect and compare abnormal brain areas objectively and quantitatively.
METHODS: Twenty-six patients with probable AD (mean age +/- SD, 66 +/- 9 y; mean Mini-Mental State Examination score, 22.5 +/- 4.2) and 6 nondemented healthy volunteers (mean age, 63 +/- 11 y) were studied with HMPAO SPECT and 18F-FDG PET. All images underwent the same processing steps, including 12-mm gaussian smoothing, spatial normalization, and z transformation with respect to normal average and SD. Thresholding of z maps was used to detect abnormal voxels.
RESULTS: The overall correlation between PET and SPECT across the entire brain was significant but not close (average r = 0.43). The best correspondence was found in the temporoparietal and posterior cingulate association cortices. There, the number of abnormal voxels for PET correlated strongly with the number for SPECT (r = 0.90 at a z threshold of -2.25), but tracer uptake reductions were significantly more pronounced for PET than for SPECT. Discordant findings were most frequently seen in the temporobasal and orbitofrontal areas (PET low, SPECT high) and in the cerebellum, parahippocampal cortex, and midcingulate cortex (PET high, SPECT low). The correlation between dementia severity and the number of abnormal voxels was closer for PET than for SPECT. Separation of patients from healthy volunteers by counting the number of abnormal voxels was possible over a much wider range of z thresholds with PET than with SPECT.
CONCLUSION: Correspondence between 18F-FDG PET and HMPAO SPECT is limited to the main finding of temporoparietal and posterior cingulate functional impairment in mild to moderate AD. The distinction between healthy volunteers and patients is less sensitive to threshold selection with PET than with SPECT, and findings in the frontal, temporobasal, and temporomesial cortices and in the cerebellum may differ between the 2 techniques.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11801698

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  40 in total

1.  For: Can ROI methodology/normalised tissue activities be used instead of absolute blood flow measurements in the brain?

Authors:  Durval C Costa
Journal:  Eur J Nucl Med Mol Imaging       Date:  2002-07       Impact factor: 9.236

2.  Diagnosis of suspected Alzheimer's disease is improved by automated analysis of regional cerebral blood flow.

Authors:  Bich-Ngoc-Thanh Tang; Satoshi Minoshima; Jean George; Annie Robert; Christian Swine; Patrice Laloux; Thierry Vander Borght
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-07-01       Impact factor: 9.236

3.  PET is better than perfusion SPECT for early diagnosis of Alzheimer's disease -- against.

Authors:  Alberto Pupi; Flavio Mariano Nobili
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-12       Impact factor: 9.236

4.  PET is better than perfusion SPECT for early diagnosis of Alzheimer's disease -- for.

Authors:  Kazunari Ishii; Satoshi Minoshima
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-12       Impact factor: 9.236

5.  Multivariate and univariate analysis of continuous arterial spin labeling perfusion MRI in Alzheimer's disease.

Authors:  Iris Asllani; Christian Habeck; Nikolaos Scarmeas; Ajna Borogovac; Truman R Brown; Yaakov Stern
Journal:  J Cereb Blood Flow Metab       Date:  2007-10-24       Impact factor: 6.200

6.  Selecting neuroimaging techniques: a review for the clinician.

Authors:  Joan A Camprodon; Theodore A Stern
Journal:  Prim Care Companion CNS Disord       Date:  2013-08-29

Review 7.  Brain glucose metabolism in the early and specific diagnosis of Alzheimer's disease. FDG-PET studies in MCI and AD.

Authors:  Lisa Mosconi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-04       Impact factor: 9.236

Review 8.  Emerging biomarkers in cognition.

Authors:  Meredith Wicklund; Ronald C Petersen
Journal:  Clin Geriatr Med       Date:  2013-11       Impact factor: 3.076

9.  Ways toward an early diagnosis in Alzheimer's disease: the Alzheimer's Disease Neuroimaging Initiative (ADNI).

Authors:  Susanne G Mueller; Michael W Weiner; Leon J Thal; Ronald C Petersen; Clifford R Jack; William Jagust; John Q Trojanowski; Arthur W Toga; Laurel Beckett
Journal:  Alzheimers Dement       Date:  2005-07       Impact factor: 21.566

10.  Computer-assisted diagnostic system for neurodegenerative dementia using brain SPECT and 3D-SSP.

Authors:  Kazunari Ishii; Tomonori Kanda; Takafumi Uemura; Naokazu Miyamoto; Toshiki Yoshikawa; Kenichi Shimada; Shingo Ohkawa; Satoshi Minoshima
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-01-16       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.